Operating expenses reached $29.2 million compared with $27.6 million a year ago, primarily driven by continued investment in R&D for EYP-1901 development, offset by a reduction in sales and marketing spend for DEXYCU.
Net product revenue for Yutiq was $7.4 million, up 60% Y/Y, with a customer demand of approximately 930 units.
The company reported a smaller-than-expected EPS loss of $(0.56), beating the consensus of $(0.68).
Cash, cash equivalents, and investments of $122.5 million will provide a cash runway into the second half of 2024.
Pipeline Update:
Price Action: EYPT shares are up 19.3% at $7.74 on the last check Wednesday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
